2022年第3版《NCCN非小细胞肺癌临床实践指南》更新解读

Interpretation of updated NCCN guidelines for non-small-cell lung cancer,version 3.2022

美国国家综合癌症网络(National Comprehensive Cancer Network,NCCN)是由32家世界知名癌症中心组成的非营利性联盟组织,旨于提供更优质、高效和合理的癌症患者管理模式。NCCN每年持续更新临床实践指南,指南以临床研究数据为依据,确保肿瘤领域专家和患者均能获取最新的癌症预防、筛选和治疗方法,从而达到最佳疗效。NCCN指南不仅是美国肿瘤领域临床决策的标准,而且是全球肿瘤临床实践最广泛的指南。2022年《NCCN非小细胞肺癌临床实践指南》目前更新至第3版,较2021年第7版指南主要在临床评估、分子标志物检测、围手术期治疗、放疗、晚期非小细胞肺癌靶向治疗和免疫治疗等方面进行更新。本文就新版指南更新内容进行逐一解读。

The National Comprehensive Cancer Network(NCCN)is a non-profit alliance composed of 32 world-renowned cancer centers,aiming to provide a better,more efficient and more appropriate management model for cancer patients.NCCN continuously updates clinical practice guidelines every year.The guidelines are based on clinical research evidence to ensure that oncology experts and cancer patients have access to the latest cancer prevention,screening and treatment methods to achieve the best treatment effect.The NCCN guidelines are not only the standard for clinical decision-making in the oncology field in the United States,but also the most extensive guidelines for clin-ical practice in oncology worldwide.The NCCN guidelines for the clinical diagnosis and treatment of non-small-cell lung cancer(NSCLC)is currently updated to version 3.2022.Compared with version 7,2021,the updated content of this version mainly focused on evaluation,molecular testing,perioperative treatment,and radiotherapy for NSCLC and targeted therapy and immunotherapy for advanced NSCLC.This article will interpret the updated content of the new version of the guidelines.